1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Longwood Capital Partners LLC Buys Immunomedics Inc, Celldex Therapeutics Inc, Adaptimmune Therapeutics PLC, Sells Axsome Therapeutics Inc, Aurinia Pharmaceuticals Inc, Avadel Pharmaceuticals PLC

Portola Valley, CA, based Investment company Longwood Capital Partners LLC (Current Portfolio) buys Immunomedics Inc, Celldex Therapeutics Inc, Adaptimmune Therapeutics PLC, Kura Oncology Inc, Larimar Therapeutics Inc, sells Axsome Therapeutics Inc, Aurinia Pharmaceuticals Inc, Avadel Pharmaceuticals PLC, Arvinas Inc, Kadmon Holdings Inc during the 3-months ended 2020Q2, according to the most recent filings of the investment company, Longwood Capital Partners LLC. As of 2020Q2, Longwood Capital Partners LLC owns 44 stocks with a total value of $341 million. These are the details of the buys and sells.

For the details of Longwood Capital Partners LLC's stock buys and sells, go to https://www.gurufocus.com/guru/longwood+capital+partners+llc/current-portfolio/portfolio

These are the top 5 holdings of Longwood Capital Partners LLC
  1. Adverum Biotechnologies Inc (ADVM) - 1,746,500 shares, 10.70% of the total portfolio. Shares added by 2.46%
  2. Immunomedics Inc (IMMU) - 545,000 shares, 5.67% of the total portfolio. New Position
  3. BioXcel Therapeutics Inc (BTAI) - 340,500 shares, 5.30% of the total portfolio. Shares added by 8.10%
  4. Iovance Biotherapeutics Inc (IOVA) - 590,000 shares, 4.75% of the total portfolio. Shares added by 47.68%
  5. Mersana Therapeutics Inc (MRSN) - 632,500 shares, 4.34% of the total portfolio. Shares reduced by 23.56%
New Purchase: Immunomedics Inc (IMMU)

Longwood Capital Partners LLC initiated holding in Immunomedics Inc. The purchase prices were between $9.4 and $36.53, with an estimated average price of $28.93. The stock is now traded at around $41.40. The impact to a portfolio due to this purchase was 5.67%. The holding were 545,000 shares as of .

New Purchase: Celldex Therapeutics Inc (CLDX)

Longwood Capital Partners LLC initiated holding in Celldex Therapeutics Inc. The purchase prices were between $1.61 and $13.41, with an estimated average price of $4.32. The stock is now traded at around $11.02. The impact to a portfolio due to this purchase was 3.82%. The holding were 1,000,000 shares as of .

New Purchase: Adaptimmune Therapeutics PLC (ADAP)

Longwood Capital Partners LLC initiated holding in Adaptimmune Therapeutics PLC. The purchase prices were between $2.58 and $12.1, with an estimated average price of $6.17. The stock is now traded at around $8.71. The impact to a portfolio due to this purchase was 3.42%. The holding were 1,165,000 shares as of .

New Purchase: Larimar Therapeutics Inc (LRMR)

Longwood Capital Partners LLC initiated holding in Larimar Therapeutics Inc. The purchase prices were between $12.3 and $16.76, with an estimated average price of $14.38. The stock is now traded at around $10.81. The impact to a portfolio due to this purchase was 3.02%. The holding were 823,169 shares as of .

New Purchase: Immunovant Inc (IMVT)

Longwood Capital Partners LLC initiated holding in Immunovant Inc. The purchase prices were between $13.87 and $28.44, with an estimated average price of $21.23. The stock is now traded at around $27.41. The impact to a portfolio due to this purchase was 2.5%. The holding were 350,000 shares as of .

New Purchase: Merus NV (MRUS)

Longwood Capital Partners LLC initiated holding in Merus NV. The purchase prices were between $10.5 and $17.36, with an estimated average price of $14.41. The stock is now traded at around $13.02. The impact to a portfolio due to this purchase was 2.17%. The holding were 460,000 shares as of .

Added: Kura Oncology Inc (KURA)

Longwood Capital Partners LLC added to a holding in Kura Oncology Inc by 340.66%. The purchase prices were between $7.95 and $18.81, with an estimated average price of $14.32. The stock is now traded at around $21.78. The impact to a portfolio due to this purchase was 3.22%. The holding were 872,500 shares as of .

Added: BioCryst Pharmaceuticals Inc (BCRX)

Longwood Capital Partners LLC added to a holding in BioCryst Pharmaceuticals Inc by 660.00%. The purchase prices were between $1.9 and $5.61, with an estimated average price of $3.96. The stock is now traded at around $4.58. The impact to a portfolio due to this purchase was 2.31%. The holding were 1,900,000 shares as of .

Added: Relmada Therapeutics Inc (RLMD)

Longwood Capital Partners LLC added to a holding in Relmada Therapeutics Inc by 157.83%. The purchase prices were between $31.59 and $49.98, with an estimated average price of $42.11. The stock is now traded at around $39.48. The impact to a portfolio due to this purchase was 1.89%. The holding were 234,500 shares as of .

Added: Iovance Biotherapeutics Inc (IOVA)

Longwood Capital Partners LLC added to a holding in Iovance Biotherapeutics Inc by 47.68%. The purchase prices were between $27.21 and $41, with an estimated average price of $32.94. The stock is now traded at around $28.97. The impact to a portfolio due to this purchase was 1.53%. The holding were 590,000 shares as of .

Added: Applied Therapeutics Inc (APLT)

Longwood Capital Partners LLC added to a holding in Applied Therapeutics Inc by 78.43%. The purchase prices were between $29.41 and $51.23, with an estimated average price of $41.82. The stock is now traded at around $26.03. The impact to a portfolio due to this purchase was 0.85%. The holding were 182,000 shares as of .

Added: IVERIC bio Inc (ISEE)

Longwood Capital Partners LLC added to a holding in IVERIC bio Inc by 394.60%. The purchase prices were between $3.06 and $6.6, with an estimated average price of $4.15. The stock is now traded at around $4.92. The impact to a portfolio due to this purchase was 0.82%. The holding were 687,500 shares as of .

Sold Out: Aurinia Pharmaceuticals Inc (AUPH)

Longwood Capital Partners LLC sold out a holding in Aurinia Pharmaceuticals Inc. The sale prices were between $14.12 and $18.33, with an estimated average price of $15.98.

Sold Out: Constellation Pharmaceuticals Inc (CNST)

Longwood Capital Partners LLC sold out a holding in Constellation Pharmaceuticals Inc. The sale prices were between $28.63 and $49.79, with an estimated average price of $35.94.

Sold Out: Marinus Pharmaceuticals Inc (MRNS)

Longwood Capital Partners LLC sold out a holding in Marinus Pharmaceuticals Inc. The sale prices were between $1.49 and $3.18, with an estimated average price of $2.3.

Sold Out: Global Blood Therapeutics Inc (GBT)

Longwood Capital Partners LLC sold out a holding in Global Blood Therapeutics Inc. The sale prices were between $48.73 and $81.82, with an estimated average price of $68.29.

Sold Out: Zafgen Inc (ZFGN)

Longwood Capital Partners LLC sold out a holding in Zafgen Inc. The sale prices were between $8.68 and $13.92, with an estimated average price of $10.1.

Sold Out: Arbutus Biopharma Corp (ABUS)

Longwood Capital Partners LLC sold out a holding in Arbutus Biopharma Corp. The sale prices were between $0.91 and $2.36, with an estimated average price of $1.63.



Here is the complete portfolio of Longwood Capital Partners LLC. Also check out:

1. Longwood Capital Partners LLC's Undervalued Stocks
2. Longwood Capital Partners LLC's Top Growth Companies, and
3. Longwood Capital Partners LLC's High Yield stocks
4. Stocks that Longwood Capital Partners LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)